Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens

European Journal of Pharmacology

Volumn 351, Issue 2, 1998, Pages 163-171

  Ichikawa, Junji ^a   Kuroki, Toshihide ^a   Dai, Jin ^a   Meltzer, Herbert Y ^a  

^a Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

5 HT (5 hydroxytryptamine, serotonin); Antipsychotic drug; Cortex, medial prefrontal; MDL 100,907; Microdialysis, in vivo; Nucleus accumbens; Rat

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPEROZIDE; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SEROTONIN ANTAGONIST; SULPIRIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FLUOROBENZENES; HALOPERIDOL; MALE; NUCLEUS ACCUMBENS; PIPERIDINES; PIRENZEPINE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN ANTAGONISTS; TIME FACTORS;

EID: 0031863323     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00308-2     Document Type: Article

References (45)

1. Abi-Dargham, A., Laruelle, M., Aghajanian, G.K., Charney, D., Krystal, J., 1997. The role of serotonin in the pathophysiology and treatment of schizophrenia. J. Neuropsychiatr. Clin. Neurosci. 9, 1-17.
2. Adell, A., Carceller, A., Artigas, F., 1991. Regional distribution of extracellular 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in the brain of freely moving rats. J. Neurochem. 56, 709-712.
3. 1B receptors. Neuropharmacology 35, 213-222.
4. 1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY100635, has partial agonist properties. Eur. J. Pharmacol. 304, 15-21.
5. Banov, M.D., Zarate, C.A., Tohen, M., Scialabba, D., Wines, J.D., Kolbrener, M., Kim, J.-W., Cole, J.O., 1994. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J. Clin. Psychiatry 55, 295-300.
6. Beasley, C.M., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., Hamilton, S., Hamilton, S., The Olanzapine HGAD Study Group, 1996. Olanzapine vs. placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14, 111-123.
7. Breier, A., 1995. Serotonin, schizophrenia and antipsychotic drug action. Schizophr. Res. 14, 187.
8. Buhot, M.-C., 1997. Serotonin receptors in cognitive behaviors. Curr. Opin. Neurobiol. 7, 243-254.
9. Calabrese, J.R., Kimmel, S.E., Woyshville, M.J., Rapport, D.J., Faust, C.J., Thompson, P.A., Meltzer, H.Y., 1996. Clozapine for treatment-refractory mania. Am. J. Psychiatry 153, 759-764.
10. Chen, N.-H., Reith, E.A., 1995. Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (±)-8-hydroxy-2-(di-n-propylamino)tetralin. J. Neurochem. 64, 1585-1597.
11. Chouinard, G., Vainer, J.L., Belanger, M.-C., Turnier, L., Beaudry, P., Roy, J.-Y., Miller, R., 1994. Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 18, 1129-1141.
12. Dassa, D., Kaladjian, A., Azorin, J.M., Giudicelli, S., 1993. Clozapine in the treatment of psychotic refractory depression. Br. J. Psychiatry 163, 822-824.
13. Davis, K.L., Kahn, R.S., Grant, K., Davidson, M., 1991. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148, 1474-1486.
14. 2 receptor antagonist, ritanserin. J. Neurochem. 59, 1459-1466.
15. Drescher, K., Hetey, L., 1988. Influence of antipsychotics and serotonin antagonists on presynaptic receptors modulating the release of serotonin in synaptosomes of the nucleus accumbens of rats. Neuropharmacology 27, 31-36.
16. Ferré, S., Artigas, F., 1995. Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism. Neurosci. Lett. 187, 61-64.
17. Gallager, D.W., Aghajanian, G.K., 1976. Effects of antipsychotic drugs on the firing of dorsal raphe cells. Eur. J. Pharmacol. 39, 341-355.
18. Hertel, P., Nomikos, G.G., Iuro, M., Svensson, T.H., 1996. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology 124, 74-86.
19. 2-adrenoceptor antagonism. Neuropsychopharmacology 17, 44-55.
20. Hertel, P., Nomikos, G.G., Svensson, T.H., 1997b. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine. Br. J. Pharmacol. 122, 1639-1646.
21. 1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. Life Sci. 48, 1779-1786.
22. Ichikawa, J., Meltzer, H.Y., 1995. Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur. J. Pharmacol. 281, 255-261.
23. Iyer, R.N., Bradberry, C.W., 1996. Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J. Pharmacol. Exp. Ther. 277, 40-47.
24. Kalén, P., Strecker, R.E., Rosengren, F., Björklund, A., 1988. Endogenous release of neuronal serotonin and 5-hydroxyindoleacetic acid in the caudate-putamen of the rat as revealed by intracerebral dialysis coupled to high-performance liquid chromatography with fluorometric detection. J. Neurochem. 51, 1422-1435.
25. 2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther. 277, 968-981.
26. 1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex. Brain Res. 743, 357-361.
27. 1A receptors. Eur. J. Pharmacol. 260, 79-83.
28. 2 receptors. Psychopharmacology 112, S40-S54.
29. Leysen, J.E., Gommeren, W., Schotte, A., 1996. Serotonin receptor subtypes: possible roles and implications in antipsychotic drug action. In: Kane, J.M., Möller, H.-J., Awouters, F. (Eds.), Serotonergic Mechanisms in Antipsychotic Treatment. Marcel Dekker, New York, pp. 51-76.
30. 1A receptors in human brain tissue. Eur. J. Pharmacol. 221, 397-398.
31. Matos, F.F., Urban, C., Yocca, F.D., 1996. Serotonin (5-HT) release in the dorsal raphe and hippocampus: raphe control of somatodendritic and terminal 5-HT release. J. Neural Transm. 103, 173-190.
32. i values. J. Pharmacol. Exp. Ther. 251, 238-246.
33. Parsa, M., Ramirez, L.F., Loula, E.C., Meltzer, H.Y., 1991. Effect of clozapine on psychotic depression and parkinsonism. J. Clin. Psychopharmacol. 11, 330-331.
34. Parsons, L.H., Justice, J., 1993. Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Brain Res. 606, 195-199.
35. Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
36. Pettersson, E., 1995. Studies of four novel diphenylbutylpiperazinepyridyl derivatives on release and inhibition of reuptake of dopamine, serotonin and noradrenaline by rat brain in vitro. Eur. J. Pharmacol. 282, 131-135.
37. Petty, F., Kramer, G., Moeller, M., 1994. Does learned helplessness induction by haloperidol involve serotonin mediation?. Pharmacol. Biochem. Behav. 48, 671-676.
38. Ranjan, R., Meltzer, H.Y., 1996. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol. Psychiatry 40, 253-258.
39. Roth, B.L., Meltzer, H.Y., 1995. Serotonin and schizophrenia. In: Bloom, F.E., Kupfer, D.J. (Eds.), Psychopharmacology: the Fourth Generation of Progress. Raven Press, New York, pp. 1215-1227.
40. Schotte, A., Janssen, P.F.M., Gommeren, W., Luyten, W.H.M.L., van Gompel, P., Lesage, A.S., DeLoore, K., Leysen, J.E., 1996. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124, 57-73.
41. Seeger, T.F., Seymour, P.A., Schmidt, A.W., Zorn, S.H., Schulz, D.W., Lebel, L.A., McLean, S., Guanowsky, V., Howard, H.R., Lowe, J.A., Heym, J., 1995. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther. 275, 101-113.
42. 2 receptor antagonist MDL-100,907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther. 266, 684-691.
43. Tanda, G., Frau, R., Di Chiara, G., 1996. Chronic desipramine and fluoxetine differentially affect extracellular dopamine in the rat prefrontal cortex. Psychopharmacology 127, 83-87.
44. 2 agonist, DOI, on 5-HT neuronal firing in the dorsal raphe nucleus and 5-HT release and metabolism in the frontal cortex. Br. J. Pharmacol. 99, 221-222.
45. Zarate, C.A., Tohen, M., Banov, M.D., Weiss, M.K., Cole, J.O., 1995. Is clozapine a mood stabilizer?. J. Clin. Psychiatry 56, 108-112.